AEON
AEON Biopharma, Inc.1.0300
+0.1660+19.2%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
14.21MP/E (TTM)
0.35Basic EPS (TTM)
2.98Dividend Yield
0%Recent Filings
8-K
AEON names new CFO
AEON Biopharma appointed John Bencich as CFO effective March 9, 2026, with $450K base and 40% target bonus, plus 754,717 RSUs and 235,849 PSUs tied to NYSE compliance by year-end. This bolsters finance leadership amid regulatory pushes. They upped the Inducement Plan share pool to 2M shares. Leadership tunes up.
8-K
Note exchange closes, debt cut
AEON Biopharma closed its Daewoong note exchange on January 21, 2026, swapping up to $15M old convertible notes for 11.9M shares, 11.2M pre-funded warrants, a $1.5M new note, and warrants for 8M shares—slashing debt while diluting equity. Stockholders also greenlit the amended 2023 equity plan and PIPE second closing next week for 4.6M shares plus warrants. Shares outstanding hit 24M post-exchange. Debt drops sharply.
8-K
ABP-450 biosimilar presentation
AEON Biopharma posted its January 2026 corporate presentation detailing ABP-450, a Botox biosimilar targeting all 12 therapeutic indications in a $3.5B+ U.S. market. It boasts 100% primary structure identity and highly similar potency to Botox. FDA Type 2a meeting set for January 21. Analytical similarity drives full-label hopes.
8-K
Daewoong note exchange signed
AEON Biopharma signed an exchange agreement on December 15, 2025, to swap Daewoong's $15M convertible notes plus accrued interest for ~23.1M common shares, a $1.5M new note due 2030 at 15.79% interest, and warrants for 8M shares at $1.09392. Closing hinges on stockholder approval expected January 21, 2026. Debt slashed over 90%. Daewoong gains board seat.
8-K
AEON posts biosimilar update
AEON Biopharma posted its December 2025 corporate presentation under Regulation FD, spotlighting November 2025 milestones: positive biosimilarity data for ABP-450, $6M PIPE financing, and Daewoong note conversion pending shareholder approval. Analytical results show 100% amino acid sequence identity to BOTOX and highly similar potency. FDA Type 2a meeting set for January 21, 2026. Shareholder vote holds the key.
IPO
Employees
Sector
Industry
ABVC
ABVC Biopharma, Inc.
2.06-0.01
AIBT
Aibotics Inc.
0.00+0.00
ASBP
Aspire Biopharma Holdings, Inc.
0.10-0.00
ATAI
Atai Beckley N.V
4.23+0.09
ATHA
Athira Pharma, Inc.
3.88+0.03
ATHE
Alterity Therapeutics Limited
3.07+0.06
AUPH
Aurinia Pharmaceuticals Inc
15.85+0.16
BMRN
BioMarin Pharmaceutical Inc.
51.77-0.35
IONS
Ionis Pharmaceuticals, Inc.
78.37-1.39
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12